Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Adenocarcinoma of Lung × pembrolizumab × Clear all

Phase

Phase 2 6 Phase 1 4 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 84 Carcinoma, Non-Small-Cell Lung 75 Lung Neoplasms 20 Melanoma 17 Squamous Cell Carcinoma of Head and Neck 16 Triple Negative Breast Neoplasms 11 Stomach Neoplasms 10 Head and Neck Neoplasms 10 Carcinoma, Renal Cell 10 Breast Neoplasms 10 Carcinoma 9 Neoplasms 8 Neoplasm Metastasis 8 Endometrial Neoplasms 7 Urinary Bladder Neoplasms 6 Carcinoma, Hepatocellular 6 Colorectal Neoplasms 5 Carcinoma, Transitional Cell 5 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Thoracic Neoplasms 3 Skin Neoplasms 3 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Lung Diseases 3 Gallbladder Neoplasms 3

Interventions

Radiotherapy 11 Carboplatin 11 Paclitaxel 8 Cisplatin 6 Gefitinib 4 Docetaxel 4 Pemetrexed 3 Mastectomy, Segmental 3 ceritinib 2 Vinorelbine 2 Taxes 2 Radiation 2 Gemcitabine 2 Etoposide 2 Bevacizumab 2 pembrolizumab 1 pegfilgrastim 1 lorlatinib 1 lazertinib 1 efaproxiral 1 Therapeutics 1 Thalidomide 1 Surgical Procedures, Operative 1 Nivolumab 1 Neoadjuvant Therapy 1 Ipilimumab 1 Immunohistochemistry 1 Immunoglobulin G 1 Filgrastim 1 Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04339218 2026-01-30

CRYOMUNE

Institut Bergonié

Phase 3 Recruiting

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡